22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Attention, Connecticut employers. October 1, 2019, marks the implementation of two new Connecticut l...
Read More >
This week, the World Health Organization upgraded the global risk of the new coronavirus (COVID-19) ...
Read More >
Q: An employee in my company has requested intermittent leave as an accommodation for what he claims...
Read More >
In the first post-Epic Systems decision regarding arbitration agreements, the NLRB has underscored j...
Read More >
Here's the timetable for EEO-1 comp data reporting. Late last week, the Equal Employment Opportunit...
Read More >
he last time the Department of Justice’s Antitrust Division and the Federal Trade Commission (the A...
Read More >